[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]
[IP] Rapid acting insulin and pump
Rapid-Acting Insulin Compatible With Pump-Delivered Continuous Insulin
Infusion Therapy WESTPORT, CT (Reuters Health) Jan 16 - Results of a new
study indicate the rapid-acting insulin analog, insulin aspart, is safe and
effective for continuous subcutaneous insulin infusion (CSII) therapy. Dr.
Bruce W. Bode of Atlanta Diabetes Associates in Georgia, and Dr. Poul Strange
of Novo Nordisk Pharmaceuticals in Princeton, New Jersey, report their study
results in the January issue of Diabetes Care. In a single-center randomized
open-label study, 19 patients received CSII with insulin aspart, while 10
received CSII with buffered regular human insulin. Bolus doses of insulin
aspart were given immediately prior to meals, and bolus doses of human
insulin 30 minutes before meals. The study lasted for 7 weeks. Insulin aspart
and buffered regular human insulin performed equally well in controlling
daily blood glucose levels and maintaining glycosylate hemoglobin levels.
"Insulin aspart appears to have less hypoglycemia than regular insulin in
pump patients and is definitely more convenient," Dr. Bode told Reuters
Health. He pointed out that, currently, buffered regular insulin is the only
approved insulin for pumps. "Insulin aspart is a fast-acting insulin analogue
that is comparable to Lilly's lispro (humalog). The benefit is that it is
compatible and efficacious in pumps and will probably get FDA approval," Dr.
Bode added. Diabetes Care 2001;24:69-72.
<A HREF="http://transplantation.medscape.com/reuters/prof/2001/01/01.17/20010116clin002.html">Rapid-Acting Insulin Compatible With Pump-Delivered Continuous Insulin
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml